Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voriconazole bioavailability in critically ill ICU patients
NL-OMON40908Phase 4Withdrawn
- Sponsor
- University Medical Center Groningen
- Start
- May 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of voriconazole in invasive aspergillosis (IA) and invasive mycoses, sponsored by University Medical Center Groningen. Primary endpoint: Absolute bioavailability of voriconazole. Planned start May 2014; status: withdrawn.
02
Drugs
voriconazole
03
Conditions
invasive aspergillosis (IA)invasive mycoses
Beyond the preview
Go deeper on NL-OMON40908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40908.